Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2018-04-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于2017年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2017 annual profit distribution plan of the company 嘉事堂药业股份有限公司. It includes details about the profit distribution proposal, board and supervisory committee approvals, and independent director opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related approvals. The document length is 1663 characters, which is relatively short and typical for an announcement rather than a full report. It explicitly states the dividend amount and the decision process, which aligns with a Notice of Dividend Amount filing rather than an Annual Report or Earnings Release. Therefore, the document is best classified as a Notice of Dividend Amount (DIV).
2018-04-25 Chinese
华泰联合证券有限责任公司关于公司内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report verification opinion issued by Huatai United Securities Co., Ltd., acting as the sponsor institution for Jiashitang Pharmaceutical Co., Ltd. It references the 2017 internal control self-evaluation report and provides detailed standards for internal control defect classification, evaluation scope, and conclusions on the effectiveness of internal controls. The document is a verification opinion on the internal control self-evaluation report rather than the report itself. It does not contain full financial statements or comprehensive financial data but rather an audit or review opinion on internal controls. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document length is 3227 characters, which is consistent with a detailed audit opinion rather than a brief announcement or a full annual report. Therefore, the appropriate classification is AR with high confidence. FY 2017
2018-04-25 Chinese
华泰联合证券有限责任公司关于公司内部控制规则落实情况自查表的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Huatai United Securities Co., Ltd., acting as the sponsor for Jiashitang Pharmaceutical Co., Ltd., regarding the company's internal control rules self-assessment form. It references regulatory guidelines and confirms the adequacy and implementation of internal control systems. The document is short (739 characters) and primarily consists of an attestation or certification by the sponsor representatives. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a compliance-related certification rather than a full audit report or annual report.
2018-04-25 Chinese
独立董事2017年度述职报告（吴剑）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2017 Annual Work Report" and contains detailed descriptions of the independent director's activities, attendance at board and shareholder meetings, opinions on company matters, supervision of governance and financial disclosures, and other duties performed during the year 2017. It is a narrative report on the independent director's role and oversight rather than a financial report or announcement. The document length is 2929 characters, which is relatively short but contains substantive content about governance and director duties. This fits best under the category of Board/Management Information (MANG), which covers announcements or reports related to company board members and senior management activities. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) because it focuses on the independent director's report rather than financial statements or regulatory compliance filings. Therefore, the classification is MANG with high confidence.
2018-04-25 Chinese
独立董事关于第五届董事会第二十三次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of certain board meeting matters, specifically the 2017 profit distribution plan and the 2018 anticipated related party transactions. It references compliance with governance rules and laws, and it is signed by the independent directors. The document does not contain financial statements or detailed financial data but rather expresses an independent directors' pre-approval opinion on board matters. This fits the category of Board/Management Information (MANG), which includes announcements related to board decisions and management opinions. The document length is short (1155 characters), and it is not a full report or financial statement, nor is it an announcement of a report publication. Therefore, the best classification is MANG with high confidence.
2018-04-25 Chinese
2017年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2017 by 嘉事堂药业股份有限公司. It extensively discusses the company's internal control environment, risk assessment, control activities, and evaluation conclusions regarding internal control effectiveness. It references regulatory standards related to internal control evaluation and provides detailed descriptions of control mechanisms, audit functions, and governance structures. The document is about internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control self-assessment. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2017
2018-04-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.